A phase I trial of ad.hIFN-β gene therapy for glioma

Molecular Therapy

Volumn 16, Issue 3, 2008, Pages 618-626

  Chiocca, E Antonio ^a   Smith, Katie M ^b   McKinney, Byron ^b   Palmer, Cheryl A ^c   Rosenfeld, Steven ^d   Lillehei, Kevin ^e   Hamilton, Allan ^f   DeMasters, Betty K ^e   Judy, Kevin ^g   Kirn, David ^h  

^a OHIO STATE UNIVERSITY   (United States)

^b BIOGEN   (United States)

^c University of Alabama at Birmingham   (United States)

^d Columbia College of Physicians and Surgeons ^*  (United States)

^e UNIVERSITY OF COLORADO   (United States)

^f UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^g HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^h Jennerex Biotherapeutics   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; ALANINE AMINOTRANSFERASE; ANTINEOPLASTIC AGENT; BETA INTERFERON; CARMUSTINE; DNA; GAMMA GLUTAMYLTRANSFERASE; NITROSOUREA; PROCARBAZINE;

ADULT; AGED; AMNESIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ANXIETY DISORDER; APOPTOSIS; ARTICLE; ATAXIA; BLOOD ANALYSIS; BLURRED VISION; BODY TEMPERATURE; BRAIN DISEASE; BRAIN HEMORRHAGE; BRAIN INFARCTION; CANCER SURGERY; CANDIDIASIS; CARDIOVASCULAR DISEASE; CATHETER INFECTION; CLINICAL ARTICLE; CLINICAL TRIAL; CLONIC SEIZURE; COGNITIVE DEFECT; CONFUSION; CONNECTIVE TISSUE DISEASE; CONSCIOUSNESS DISORDER; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CONTUSION; CONVULSION; DEEP VEIN THROMBOSIS; DEHYDRATION; DEPRESSION; DIZZINESS; DRUG DISTRIBUTION; DRUG INTOXICATION; DRUG MEGADOSE; DYSPEPSIA; DYSPHASIA; DYSPNEA; ECCHYMOSIS; EDEMA; ERYTHEMA; EYE DISEASE; FALLING; FATIGUE; FEMALE; FEVER; GAIT DISORDER; GASTROINTESTINAL TOXICITY; GENE IDENTIFICATION; GENE LOCATION; GLIOMA; HEADACHE; HEMATOCRIT; HEMIPARESIS; HEMIPLEGIA; HERPES SIMPLEX; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYPERGLYCEMIA; HYPERREFLEXIA; HYPERTENSION; INFECTION; INFESTATION; INJURY; INSOMNIA; KIDNEY DISEASE; LETHARGY; LUNG DISEASE; LUNG EMBOLISM; MALE; MEDIASTINUM DISEASE; MEMORY DISORDER; MENTAL DISEASE; METABOLIC DISORDER; MOOD; MUSCLE WEAKNESS; MUSCULOSKELETAL DISEASE; NAUSEA; NEUROLOGIC DISEASE; NUTRITIONAL DISORDER; NYSTAGMUS; PERIPHERAL EDEMA; PERSONALITY; PHASE 1 CLINICAL TRIAL; PROPRIOCEPTION; PRURITUS; RIGOR; SENSORY DYSFUNCTION; SIDE EFFECT; SIMPLE PARTIAL SEIZURE; SINUS BRADYCARDIA; SKIN TOXICITY; SPEECH DISORDER; THORAX DISEASE; THROMBOSIS; TUMOR BIOPSY; TUMOR NECROSIS; UNSPECIFIED SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; URINE INCONTINENCE; URINE RETENTION; VASCULAR DISEASE; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; VISUAL FIELD DEFECT; VOMITING; WEIGHT REDUCTION; WOUND HEALING IMPAIRMENT;

ADENOVIRIDAE;

EID: 39849092406     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/sj.mt.6300396     Document Type: Article

References (37)

1. WK Yung M Prados VA Levin MR Fetell J Bennett MS Mahaley Intravenous recombinant interferon- β in patients with recurrent malignant gliomas: a phase I/II study J Clin Oncol 9 1991 1945 1949
2. DD Von Hoff B Metch JG Lucas SP Balcerzak SM Grunberg SE Rivkin Phase II evaluation of recombinant interferon- β (IFN- β ser) in patients with diffuse mesothelioma: a Southwest Oncology Group study J Interferon Res 10 1990 531 534
3. XQ Qin N Tao A Dergay P Moy S Fawell A Davis Interferon- β gene therapy inhibits tumor formation and causes regression of established tumors in immune-deficient mice Proc Natl Acad Sci USA 95 1998 14411 14416
4. XQ Qin C Beckham JL Brown M Lukashev J Barsoum Human and mouse IFN- β gene therapy exhibits different anti-tumor mechanisms in mouse models Mol Ther 4 2001 356 364
5. M Odaka DH Sterman R Wiewrodt Y Zhang M Kiefer KM Amin Eradication of intraperitoneal and distant tumor by adenovirus-mediated interferon- β gene therapy is attributable to induction of systemic immunity Cancer Res 61 2001 6201 6212
6. MC Chamberlain A phase II trial of intra-cerebrospinal fluid α interferon in the treatment of neoplastic meningitis Cancer 94 2002 2675 2680
7. L Jacobs AM Salazar R Herndon PA Reese A Freeman R Jozefowicz Intrathecally administered natural human fibroblast interferon reduces exacerbations of multiple sclerosis. Results of a multicenter, double-blind study Arch Neurol 44 1987 589 595
8. TW Trask RP Trask E Aguilar-Cordova HD Shine PR Wyde JC Goodman Phase I study of adenoviral delivery of the HSV-tk gene and ganciclovir administration in patients with recurrent malignant brain tumors Mol Ther 1 2000 195 203
9. SL Eck JB Alavi K Judy P Phillips A Alavi D Hackney Treatment of recurrent or progressive malignant glioma with a recombinant adenovirus expressing human interferon- β (H5.010CMVhIFN- β ): a phase I trial Hum Gene Ther 12 2001 97 113
10. KJ Pulkkanen S Yla-Herttuala Gene therapy for malignant glioma: current clinical status Mol Ther 12 2005 585 598
11. A Immonen M Vapalahti K Tyynelä H Hurskainen A Sandmair R Vanninen AdvHSV-tk gene therapy with intravenous ganciclovir improves survival in human malignant glioma: a randomised, controlled study Mol Ther 10 2004 967 972
12. EA Chiocca KM Abbed S Tatter DN Louis FH Hochberg F Barker A phase I open-label, dose-escalation, multi-institutional trial of injection with an E1B-Attenuated adenovirus, ONYX-015, into the peritumoral region of recurrent malignant gliomas, in the adjuvant setting Mol Ther 10 2004 958 966
13. J Lane C Chutkowskil J Lanel M Butt L Tryphonas R Boyd Preclinical safety evaluation of BG00001, a replication defective adenoviral vector expressing the human interferon and β (hIFN β ) gene, following repeated intracerebral dosing in rhesus monkeys Toxicol Pathol 31 2003 140 149
14. RA Dewey G Morrissey CM Cowsill D Stone F Bolognani NJ Dodd Chronic brain inflammation and persistent herpes simplex virus 1 thymidine kinase expression in survivors of syngeneic glioma treated by adenovirus-mediated gene therapy: implications for clinical trials Nat Med 5 1999 1256 1263
15. G Fulci L Breymann D Gianni K Kurozomi SS Rhee J Yu Cyclophosphamide enhances glioma virotherapy by inhibiting innate immune responses Proc Natl Acad Sci USA 103 2006 12873 12878
16. M Johnston A Zakharov C Papaiconomou G Salmasi D Armstrong Evidence of connections between cerebrospinal fluid and nasal lymphatic vessels in humans, non-human primates and other mammalian species Cerebrospinal Fluid Res 1 2004 2
17. M Brickelmaier A Carmillo S Goelz J Barsoum XQ Qin Cytotoxicity of combinations of IFN- β and chemotherapeutic drugs J Interferon Cytokine Res 22 2002 873 880
18. TD McKee P Grandi W Mok G Alexandrakis N Insin JP Zimmer Degradation of fibrillar collagen in a human melanoma xenograft improves the efficacy of an oncolytic herpes simplex virus vector Cancer Res 66 2006 2509 2513
19. K Ikeda T Ichikawa H Wakimoto JS Silver TS Deisboeck D Finkelstein Oncolytic virus therapy of multiple tumors in the brain requires suppression of innate and elicited antiviral responses Nat Med 5 1999 881 887
20. H Kambara Y Saeki EA Chiocca Cyclophosphamide allows for in vivo dose reduction of a potent oncolytic virus Cancer Res 65 2005 11255 11258
21. G Fulci N Dmitrieva D Gianni EJ Fontana X Pan Y Lu Depletion of peripheral macrophages and brain microglia increases brain tumor titers of oncolytic viruses Cancer Res 67 2007 9398 9406
22. D Kirn RL Martuza J Zwiebel Replication-selective virotherapy for cancer: biological principles, risk management and future directions Nat Med 7 2001 781 787
23. EA Chiocca Oncolytic viruses Nat Rev Cancer 2 2002 938 950
24. JA McCart JM Ward J Lee Y Hu HR Alexander SK Libutti Systemic cancer therapy with a tumor-selective vaccinia virus mutant lacking thymidine kinase and vaccinia growth factor genes Cancer Res 61 2001 8751 8757
25. SH Thorne DH Kirn Future directions for the field of oncolytic virotherapy: a perspective on the use of vaccinia virus Expert Opin Biol Ther 4 2004 1307 1321
26. E Tyminski S Leroy K Terada DM Finkelstein JL Hyatt MK Danks Brain tumor oncolysis with replication-conditional herpes simplex virus type 1 expressing the prodrug-activating genes, CYP2B1 and secreted human intestinal carboxylesterase, in combination with cyclophosphamide and irinotecan Cancer Res 65 2005 6850 6857
27. T Reid E Galanis J Abbruzzese D Sze LM Wein J Andrews Hepatic arterial infusion of a replication-selective oncolytic adenovirus (dl1520): phase II viral, immunologic, and clinical endpoints Cancer Res 62 2002 6070 6079
28. DH Sterman CT Gillespie RG Carroll CM Coughlin EM Lord J Sun Interferon β adenoviral gene therapy in a patient with ovarian cancer Nat Clin Pract Oncol 3 2006 633 639
29. MJ Mastrangelo HC Maguire Jr LC Eisenlohr CE Laughlin CE Monken PA McCue Intratumoral recombinant GM-CSF-encoding virus as gene therapy in patients with cutaneous melanoma Cancer Gene Ther 6 1999 409 422
30. SH Thorne TH Hwang DH Kirn Vaccinia virus and oncolytic virotherapy of cancer Curr Opin Mol Ther 7 2005 359 365
31. KD Fisher Y Stallwood NK Green K Ulbrich V Mautner LW Seymour Polymer-coated adenovirus permits efficient retargeting and evades neutralising antibodies Gene Ther 8 2001 341 348
32. AJ Bett V Krougliak FL Graham DNA sequence of the deletion/insertion in early region 3 of Ad5 dl309 Virus Res 39 1995 75 82
33. S Chang M Vogelbaum FF Lang S Haines S Kunwar EA Chiocca GNOSIS: guidelines for neuro-oncology: standards for investigational studies—reporting of surgically based therapeutic clinical trials J Neurooncol 82 2007 211 220
34. GR Harsh TS Deisboeck DN Louis J Hilton M Colvin JS Silver Thymidine kinase activation of ganciclovir in recurrent malignant gliomas: a gene-marking and neuropathological study J Neurosurg 92 2000 804 811
35. FF Lang JM Bruner GN Fuller K Aldape MD Prados S Chang Phase I trial of adenovirus-mediated p53 gene therapy for recurrent glioma: biological and clinical results J Clin Oncol 21 2003 2508 2518
36. AM Puumalainen M Vapalahti RS Agrawal M Kossila J Laukkanen P Lehtolainen β -galactosidase gene transfer to human malignant glioma in vivo using replication-deficient retroviruses and adenoviruses Hum Gene Ther 9 1998 1769 1774
37. KA Roth In situ Detection of Apoptotic Neurons 2002 Humana Press Totowa, NJ